|

Later-line therapy Clinical Trials

2 actively recruiting trials

Top Sponsors

  • Peking Union Medical College Hospital2

Indications

  • Pancreatic Cancer2
  • Cancer2
  • Resectable Carcinoma1
  • Locally Advanced1

Other2 trials

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Borderline Resectable or Locally Advanced Pancreatic Cancer
N/A
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
N/A

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.